Irbesartan-Comp Puren (Hydrochlorothiazide, Irbesartan)

Irbesartan-Comp Puren is an antihypertensive agent that acts on the renin‑angiotensin‑aldosterone system and renal sodium handling.

• Hypertension: reduces systolic and diastolic blood pressure by vasodilation and decreased plasma volume.
• Essential hypertension: improves long‑term cardiovascular risk control in patients with primary high blood pressure.
• Hypertension with fluid retention: adds diuretic effect to control edema while lowering pressure.

• Irbesartan selectively blocks AT1 receptors, preventing angiotensin II‑mediated vasoconstriction and aldosterone release, which lowers systemic vascular resistance. Hydrochlorothiazide inhibits Na⁺/Cl⁻ reabsorption in the distal convoluted tubule, increasing urinary sodium and water excretion, thereby reducing plasma volume and contributing to blood‑pressure reduction.

Common Side Effects

• Dizziness: transient light‑headedness, especially after the first dose.
• Headache: mild to moderate intensity.
• Fatigue: general feeling of tiredness.
• Increased urination: due to the diuretic component.
• Electrolyte imbalance: mild changes in potassium or sodium levels.
• Elevated blood glucose: modest rise in fasting glucose.

Serious or Rare Side Effects

• Angioedema: swelling of face, lips, tongue, or throat.
• Severe dehydration: excessive fluid loss leading to hypotension.
• Hyperkalemia: dangerously high potassium levels.
• Acute renal impairment: sudden decline in kidney function.
• Anaphylactic reaction: severe allergic response.
• Hepatic injury: rare liver enzyme elevations.

Before initiating therapy, consider the following precautions:

• Blood pressure monitoring: check regularly to avoid hypotension.
• Renal function assessment: evaluate serum creatinine and eGFR.
• Electrolyte surveillance: monitor potassium and sodium levels.
• Hepatic impairment: use with caution in patients with liver disease.
• Pregnancy and lactation: safety not established; avoid unless clearly needed.
• Store at below 25°C: keep in the original container, protect from moisture and light.

Irbesartan-Comp Puren may interact with several medicines.

Major Interactions (Avoid)

• Aliskiren: combined renin‑angiotensin blockade can increase renal risk.
• Potassium‑sparing diuretics or supplements: risk of hyperkalemia.
• NSAIDs: may blunt antihypertensive effect and impair renal function.
• Lithium: increased lithium concentrations and toxicity.

Moderate Interactions (Monitor Closely)

• ACE inhibitors: additive blood‑pressure lowering, monitor for hypotension.
• Other antihypertensives: dose adjustments may be required.
• CYP2C9 inhibitors (e.g., amiodarone): may raise irbesartan levels.
• CYP3A4 inhibitors (e.g., clarithromycin): may increase exposure to irbesartan.